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Abstract
For anticancer drug therapy, it is critical to kill those cells with highest tumorigenic potential, even when they comprise a
relatively small fraction of the overall tumor cell population. We have used the established NCI/DTP 60 cell line growth
inhibition assay as a platform for exploring the relationship between chemical structure and growth inhibition in both
tumorigenic and non-tumorigenic cancer cell lines. Using experimental measurements of ‘‘take rate’’ in ectopic implants as a
proxy for tumorigenic potential, we identified eight chemical agents that appear to strongly and selectively inhibit the
growth of the most tumorigenic cell lines. Biochemical assay data and structure-activity relationships indicate that these
compounds act by inhibiting tubulin polymerization. Yet, their activity against tumorigenic cell lines is more selective than
that of the other microtubule inhibitors in clinical use. Biochemical differences in the tubulin subunits that make up
microtubules, or differences in the function of microtubules in mitotic spindle assembly or cell division may be associated
with the selectivity of these compounds.
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Introduction
The aggressiveness of different kinds of tumor cells derived from
human patients can be assessed in terms of their tumorigenic
potential in mouse xenograft models. For example, tumorigenic
potential in mouse xenografts has recently been used to define the
cancer ‘‘stem cells’’, which presumably correspond to the subpopu-
lation of malignant cells that drive the formation and growth of the
tumor [1]. Accordingly, it has been postulated that some cancers are
composed of a heterogeneous collection of cells, only a minority of
which are capable of forming new tumors [2]. These cells can be
enriched from heterogeneous tumor cell populations on the basis of
their expression of cell-surface markers. In breast tumors, for
example, cells co-expressing high levels of CD44 and epithelial
specific antigen (ESA) and low levels of CD24 are the tumor initiating
cells [2]. Likewise, in colon and brain cancer, subpopulations of cells
expressing high levels of CD133 (PROML1) initiate the tumors [3,4].
Most importantly, upon transplantation into immunocompromised
mice, tumor-initiating cells can fully reconstitute a tumor with
heterogeneity reminiscent of the original tumor [2–4]. Although the
concept of a cancer ‘‘stem cell’’ is still controversial, from a
therapeutic standpoint, anticancer agents directed against tumori-
genic cancer cells may be the most effective at eradicating tumors.
The drug discovery and development sector of National Cancer
Institute (NCI), the Developmental Therapeutics Program (DTP),
has utilized a panel of 60 human tumor-derived cell lines to screen
the chemotherapeutic potential of more than 75000 compounds
[5,6]. This panel of 60 cell lines is commonly known as ‘‘NCI60
cell lines.’’ The cell lines represent various leukemias, melanomas
and cancers of the lung, colon, brain, ovary, breast, prostate and
kidney [5]. Apart from their use in drug screening, the tumorigenic
potential of these cell lines has been measured by xenotransplant-
ing these cells into immunocompromised mice and assessing their
ability to form new tumors [6]. Different cell lines in the NCI60
panel display a range of tumorigenic potentials upon transplan-
tation into immunocompromised mice. The tumorigenic potential
has been recorded as each cell line’s ‘‘take-rate.’’
As a hypothesis, differences in tumorigenic potential among the
NCI cancer cell lines may reflect variations in proliferative activity
and tumor-initiating characteristics of the actual cancer cells as they
exist in the tumors of cancer patients. Thus, NCI60 cell lines
demonstrating high take rate may be more representative of tumor-
initiating cancer cells found in situ. Here, we identify compounds
from the DTP database that are most active against cell lines with
the highest take rate, and proceed to establish a putative mechanism
of action for these compounds by performing structure-activity
relationship studies, and comparing them to standard anticancer
agentswhosemechanismofactionisknown.Inaddition,differences
in tumorigenic potential and responsiveness to these agents are
shown to be related to differences in gene expression between
NCI60 cell lines with highand low tumorigenic potentials, as well as
to gene expression markers of tumorigenic cancer cells.
Results
Identification of selectively cytotoxic compounds
Growth inhibitory activity in the DTP collection of chemical
agents as represented by 2logGI50 can be compared to the four
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this approach, nine compounds having correlation coefficient
greater than 0.5 in magnitude were identified out of 34,909
compounds tested (Figure 1). All nine correlation coefficients were
positive, indicating that these agents were more active at inhibiting
cell growth in the most tumorigenic cell lines (Figure 2). Because
the expected number of compounds out of 34,909 having a
correlation coefficient exceeding 0.5 in magnitude by chance is 0.7
with a 95
th percentile of two compounds, it is very unlikely that
two or more of these nine compounds are false positives.
None of the standard anticancer agents in the DTP database
surpass these nine compounds in terms of selective cytotoxic
activity against the most tumorigenic cell lines. The greatest
correlation coefficient observed among the standard anticancer
agents is 0.47 for vinblastine, which is an antimitotic agent. In fact,
antimitotic agents are the only mechanistic class showing
consistent non-negligible positive correlation with take-rate.
Despite their positive correlation coefficients, none of the
antimitotic standard anticancer agents show correlation coefficient
greater than 0.5, suggesting that the nine compounds identified in
our correlation analysis may be uniquely selective against the most
tumorigenic cell lines. Several of these nine compounds exhibit a
wide selectivity window with difference in 2logGI50 between
tumorigenic and non-tumorigenic cell lines of two or more.
Compounds 384634, 385177, 5468780, 361500 and 379512 are
comparable to all of the standard antimitotic agents in regards to
their cytotoxicity; however, their selectivity window is much wider
(Figure 3).
Inhibition of tubulin polymerization as possible
mechanism of action
The compounds identified point to a major structure-activity
relationship class: four of the compounds identified share a core
naphthyridin structure (see Figure 1). Three of these compounds
(385177, 5468780, 5468781) are structurally related, through the
presence of a naphthelene group at position R2. These structures
differ from each other based only on the positioning of one or two
methyl group on the A ring: compounds 385177 and 5468780
contain a methyl group at positions R5 and R2, respectively, while
compound 5468781 contains two methyl groups at positions R5
and R2. The other compound (384634) differs from the three
previously mentioned compounds because the group 39-methoxy
substituted benzene ring substitutes the naphthalene group at
position R2. This compound also contains a methyl group at
position R5 on ring A. The presence of the core structure common
to all the compounds in this group suggests that it may play a
cornerstone role in the mechanism of action for this cohort of
compounds.
In order to identify a possible mechanism of action, the nine
compounds were clustered together with the 168 standard
anticancer agents using the 881 key CACTVS fingerprints.
Cutting the dendrogram at a Tanimoto coefficient of 0.7, five of
the nine compounds are clustered with nine standard anticancer
agents including various antitubulin agents such as vinblastine and
vincristine. Subsequent analysis of the scientific literature revealed
that many of our compounds do indeed inhibit polymerization of
tubulin in vitro. Compound 384634 has been synthesized and has
Figure 1. Structures of nine selectively cytotoxic compounds and the core structure shared by four of these compounds.
doi:10.1371/journal.pone.0004470.g001
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tion assay [11]. Likewise, isosteres of compound 385177, 5468780
and 5468781 potently inhibit tubulin polymerization [12]. It is
highly plausible that compound 379512 is an antitubulin agent as
well, because a number of compounds containing the 2-phenyl-
quinolone ring structure have been synthesized and exhibit tubulin
polymerization [13–17]. Compound 5388755 is almost structur-
ally identical to Combretastatin A-4, which is a very potent
antitubulin agent [18].
COMPARE analysis [19] was performed to further characterize
the mechanism of action of the compounds. In COMPARE, a
correlation coefficient of 0.6 is generally taken to indicate evidence
for similar mechanisms of action between the tested and reference
compounds. The higher the correlation coefficient, the more likely
it is that the compounds share the same intracellular target [9].
The correlation coefficient of the COMPARE computations for
the eight most potent compounds and the antimitotic standard
anticancer agents reveals several compounds showing high
correlations with microtubule inhibitors colchicine, maytansine,
vinblastine and vincristine (Table 1). None of these compounds
show similarity to any of the agents from other mechanistic classes
such as topoisomerase inhibitors, alkylating agents and DNA/
Figure 2. Scatterplot of cytotoxic activity (2logGI50) for the nine compounds identified in our virtual screen as showing cytotoxic
activity, in relation to the four categories of tumorigenic potential.
doi:10.1371/journal.pone.0004470.g002
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exhibit strong correlation with taxol, which is an antimitotic agent
that acts by stabilizing microtubules.
Antitubulin activity parallels selective cytotoxicity
In order to identify the role of antitubulin activity in generating
selective cytotoxicity, we identified twelve additional DTP
compounds (Figure 4) that are structurally related to some of the
nine compounds we identified in our correlation analysis but that
lack antitubulin activity [11–15]. If antitubulin activity confers
selective cytotoxicity, these compounds with no antitubulin activity
should demonstrate no selective cytotoxicity. The scatterplot
comparing the association between cytotoxicity and take-rate for
these twelve compounds indicates that none of these compounds
show selective cytotoxicity (Figure 5), and they are largely inactive
in the cell growth inhibition assay.
Gene expression analysis
A number of previous research studies have identified CD44,
CD24, and CD133 (PROML1) as being markers for tumorigenic
potential or stem-cell-like characteristics, with CD44 and CD133
being relatively highly expressed in tumorigenic lines, and CD24
being expressed at low levels. Thus, we searched for specific genes
whose expression may be related to the selective cytotoxic activity
of the compounds identified. For this purpose, transcriptional
profiling data was mined for genes whose expression across the cell
lines correlates with tumorigenic potential. In this data set, we
found that take rate is independent of PROML1, CD44, and the
Figure 3. Selectivity windows for eight compounds identified in our virtual screen (G–N) and several standard anticancer agents
having antimicrotubule activity (A–F).
doi:10.1371/journal.pone.0004470.g003
Table 1. COMPARE analysis of eight compounds to various agents from the antimitotic activity class.
Seed Colchicine Maytansine Rhizoxin Taxol Vinblastine Vincristine
384634 0.69 0.73 0.51 0.36 0.85 0.70
385177 0.50 0.42 0.41 0.32 0.51 0.36
5468780 0.60 0.62 0.22 0.32 0.63 0.58
5468781 0.55 0.59 0.31 0.38 0.59 0.46
319428 0.27 0.37 0.24 0.27 0.53 0.35
361500 0.75 0.72 0.58 0.34 0.77 0.56
5388755 0.67 0.70 0.60 0.44 0.63 0.60
379512 0.41 0.43 0.32 0.28 0.29 0.65
doi:10.1371/journal.pone.0004470.t001
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the expression of twenty or so different tubulin isotypes (alpha,
beta, and gamma) and found no correlation with take rate.
Although candidate tumorigenicity marker genes PROML1,
CD44, and CD44-CD24 were not associated with take-rate, we
did identify genes expressed at substantially higher levels in the
more tumorigenic cell lines. On the U95A array platform, a
transcription factor (DBP), an integrin (ITGA6, two probe sets),
and a membrane skeletal protein (ADD3, two probe sets) followed
this pattern of expression. Six named genes and two unnamed
genes are expressed at substantially higher levels in the less
tumorigenic as compared to the more tumorigenic cell lines on the
U95A array platform: PTGIS, JAK1, MGC5560, XPC, NRG1,
and SULF1. On the U133A/B platform TMEM18, ACACB, and
GMCL1 were positively associated with tumorigenic potential,
along with two unnanotated probesets (229930_at and 230312_at).
No negative associations meeting our selection criteria were
identified on the U133A/B array platform. The functional
significance of putative stem cell marker genes in relation to
tumorigenicity or increased sensitivity to microtubule inhibitors is
not clear.
Discussion
By data mining the DTP archive, we are able to identify
compounds that are preferentially toxic against the most
tumorigenic of the NCI60 cell lines, based on the take rate of
the cell lines in a mouse xenograft model. We also established that
the activity of these compounds was not correlated to the
expression of cell surface stem cell markers reported in the
literature. Nevertheless, tumorigenic potential is the most
important functional relationship between the most aggressive
tumor cells and in vitro model for drug screening. Therefore, the
anticancer agents identified based on their activity against the
most tumorigenic cell lines may be considered as candidate
anticancer agents that are specifically directed against subpopu-
lations of cancer cells that drive the growth of tumors.
One of these agents (384634) has been found to inhibit
microtubule polymerization. Likewise, isosteres of three of our
agents (385177, 5468780, 5468781) have also been shown to
inhibit microtubule polymerization, suggesting a single mechanism
of action. Interestingly, Compound 5388755 is structurally related
to the potent antitubulin agent Combretastatin A-4. It is also
possible that compound 379512 acts by inhibiting tubulin
polymerization because several different agents containing the
quinolone ring structure have demonstrated antitubulin activity.
COMPARE analysis corroborates the similarities between the
anticancer agents identified here and various different microtubule
inhibitors. With the exception of compound 319428, all of our
compounds show strong similarity with colchicine, maytansine,
vinblastine and vincristine. None of our compounds show
significant relationship to taxol, which acts by stabilizing
microtubules.
From our analysis, antitubulin activity is likely to be responsible
for selective cytotoxicity against tumorigenic cell lines. A select
number of structurally related compounds with no antitubulin
activity were analyzed for their pattern of cytotoxicity toward
NCI60 cell lines. None of these compounds demonstrated selective
Figure 4. Structures of compounds that are structurally related to the nine compounds identified in our virtual screen, but that do
not inhibit microtubules or cell growth.
doi:10.1371/journal.pone.0004470.g004
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Together with their antitubulin activity, the selectivity of our
compounds toward highly tumorigenic cell lines suggests that
microtubules of tumorigenic and non-tumorigenic cell lines may
differ. Interestingly, no difference in tubulin gene expression level
was observed between highly tumorigenic and non-tumorigenic
cell lines. It is plausible that observed selective cytotoxicity is not
due to difference in tubulin gene expression but rather a result of
differences in post-translational modifications (PTMs) [20].
Recently, various experimental results have supported the notion
that tubulin PTMs lead to the functional diversity of microtubules.
Many tubulin PTMs have been identified including detrysosina-
tion, glutamylation, glycylation, acetylation phosphorylation and
palmitoylation [20–22]. Differences in tubulin isotype expression
and PTMs have been associated with cell differentiation and
developmental transitions [23–25]. Because microtubules are key
to mitotic spindle assembly and cell division, differences in mitotic
spindle structure and function between tumorigenic and non-
tumorigenic cell lines may be associated with the selectivity of
these compounds.
In conclusion, we have identified a family of microtubule
inhibitors that are mostly toxic against tumorigenic cell lines.
Figure 5. Scatterplots of the cytotoxicity of several compounds lacking microtubule inhibitory activity, in relation to the four
categories of tumorigenic potential.
doi:10.1371/journal.pone.0004470.g005
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xenograft models may capture some properties of cancer cell
subpopulations that are responsible for initiating and spreading the
tumors. Therefore, we propose that this family of microtubule
inhibitors, or related compounds with similar selectivity charac-
teristics, should be considered as prime candidates for further
evaluation as anticancer agents.
Materials and Methods
Primary data
The compound growth inhibition data was obtained from the
NCI 60 cell line antitumor screen. The growth inhibitory activity
of each compound corresponds to the molar drug concentration
required to cause 50% growth inhibition (GI50). Most assays use a
maximum concentration of 0.0001 M (the cell line screen and
GI50 parameter are described in [7]). For microarray gene
expression analysis, we used five publicly-available data sets for the
NCI60 cell lines: triplicate experiments using the Affymetrix U95A
platform provided by Novartis, a single U95A data set provided by
GeneLogic, and a single Affymetrix U133A/B data set provided
by GeneLogic. The GI50 data were obtained from http://dtp.nci.
nih.gov/docs/cancer/cancer_data.html and all gene expression
data were obtained from http://dtp.nci.nih.gov/mtargets/download.
html. All gene expression and GI50 assay data are analyzed on the
log scale.
Rating of tumorigenic potential
The NCI60 cell lines have been experimentally evaluated for
tumorigenic potential by transplantation of the cell lines into
immuno-compromised mice. The experiments and results are
provided in the Anticancer Drug Development Guide [6]. For
different cell lines, these data are given either quantitatively or
qualitatively, or sometimes as ranges, as the ‘‘take rate,’’ or
proportion of attempted implants that yielded a tumor. We
converted the take rate data into four ordered categories for
analysis: 0 for no growth, 1 for 1–60% take rate, 2 for 60–80%
take rate and 3 for 80–100% take rate. Cell lines that overlap two
categories are rated at the lower category. For instance, a cell line
with 70–90% take rate is rated as category 3. These ratings of
tumorigenic potential are denoted ‘‘TP.’’
Compound selection
Compounds active against high take-rate cell lines wereidentified
by comparing the growth inhibition measurement (2log GI50) to
the four-level rating of take-rate, using Pearson correlation.
Thresholds of 0.4 and 0.5 were used to define moderate and strong
correlations. Statistical significance was assessed by calculating the
expected number of compounds out of all compounds tested that
would be expected to havea correlation exceeding a given threshold
by chance (based on applying Fisher’s Z-transformation and using a
standard normal reference distribution).
Gene expression analysis
Compounds active against cell lines that express relatively high
levels of PROML1 or CD44-CD24 were identified using Pearson
correlation coefficients between 2log10GI50 and either log scale
expression of PROML1, or the difference between log scale
expression levels of CD44 and CD24. PROML1 is represented by a
unique probeset on both platforms, CD44 is represented by two
U95A probesets and by six U133A/B probesets, and CD24 is
represented by one U95A probeset and by six U133A/B probesets.
When multiple probesets are available, all are analyzed separately,
and differences among all pairs of CD44/CD24 probesets are
analyzed separately. For all analyses, compounds for which fewer
than 50 cell lines had a GI50 value, or which had no variability in
their GI50 values, were excluded from our analysis.
Standard anticancer agents
A set of 168 compounds with anticancer activity was compiled,
and a subset of 121 of them was annotated according to their
presumed mechanism of action [8–10]. The data we used were
obtained from http://dtp.nci.nih.gov/docs/cancer/searches/
standard_mechanism_list.html, and include the following mecha-
nism of action classes and numbers of unique structures: alkylating
agents (35), antimitotic agents (13), topoisomerase 1 inhibitors (24),
topoisomerase II inhibitors (15), DNA anti-metabolites (16), and
RNA/DNA anti-metabolites (18).
Chemical structure comparisons
All compounds discussed here are part of PubChem, and all
reported structural comparisons are based on Tanimoto coeffi-
cients using the 881 key CACTVS fingerprints. Calculations of
Tanimoto coefficients and hierarchical clustering of chemical
structures based on Tanimoto coefficients was done using the
NCBI portal to PubChem (http://pubchem.ncbi.nlm.nih.gov).
We converted all compound identifiers from the DTP’s NSC
identifier to PubChem’s CID identifier for structural analysis.
COMPARE analysis
COMPARE computations for all of the potent compounds
against standard anticancer agents from various mechanistic
classes are performed. Pearson correlation coefficients correspond-
ing to high concentration of 0.0001 M are reported for a majority
of the compounds. For compounds that are tested with an
alternative high concentration, the Pearson correlation coefficients
are obtained from pairs with the closest high concentration.
Selectivity window
The selectivity window was calculated by taking the difference
between the average 2logGI50 of the most tumorigenic cell lines
(take-rate category 3) and the least tumorigenic cell lines (take-rate
category 0).
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